A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents-Reference-Cited by-同舟云学术

A novel GIP analogue, ZP 4165, enhances glucagon‐like peptide‐1‐induced body weight loss and improves glycaemic control in rodents

Published:2017-07-27 Issue:1 Volume:20 Page:60-68
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Nørregaard Pia K.¹^ORCID,Deryabina Maria A.¹,Tofteng Shelton Pernille¹,Fog Jacob U.¹,Daugaard Jens R.¹,Eriksson Per‐Olof¹,Larsen Lone F.¹,Jessen Lene¹

Affiliation:

1. Zealand Pharma A/S Glostrup Denmark

Funder

Zealand Pharma A/S

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13034

Reference26 articles.

1. The World Health Organization. Global report on diabetes 2016.http://www.who.int/diabetes/global‐report/en/. Accessed April 3 2017.

2. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

3. The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide—Regardless of Etiology and Phenotype

4. Inhibition of gastric inhibitory polypeptide signaling prevents obesity

5. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys;Molecular Metabolism;2024-10

2. Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management;Expert Review of Endocrinology & Metabolism;2024-08-28

3. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management;Life Sciences;2024-08

4. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

5. Transforming obesity: The advancement of multi-receptor drugs;Cell;2024-07